Frontlight ResearchEarly access
Taking peopleNo phase
Tofacitinib in Juvenile Idiopathic Arthritis
Key facts
- Who runs it
- Consorci Sanitari de l'Alt Penedès i Garraf
- Where
- Spain7 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 58 people, planned
- Started
- 2 Feb 2026
- Expected to end
- Dec 2027
- Type of study
- Observational
- Treatments tested
- Tofacitinib
- Record updated
- 28 October 2026
Who can take part
- Age
- Up to 18 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Diagnosis of juvenile idiopathic arthritis (JIA) documented in the medical record by the treating rheumatologist
- Documentation in the medical record of the medical indication for tofacitinib treatment, with a diagnostic justification related to JIA
- Age under 18 years at the time of the treatment indication with tofacitinib
Who cannot take part
- Participants diagnosed with any of the following conditions:
- Arthritis associated with inflammatory bowel disease
- Arthritis associated with another autoimmune disease
- Reactive arthritis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate, using real-world clinical practice data, the efficacy of tofacitinib in improving the clinical control of juvenile idiopathic arthritis (JIA) after 12 months of treatment.
The group in the trial
- Tofacitinib
Patients affected by JIA and treated with tofacitinib
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of Tofacitinib in Patients With Juvenile Idiopathic Arthritis: A Study Based on Real-world Clinical Practice Data.
- Record updated
- 28 October 2026